leronlimab will cover more indications IMO, at least in the near term, like within this decade. I am very bullish. On the other hand, with Galectin, world class Providence Portland Medical Center is running GALT's I/O trials, and they are slow. CytoDyn has done a great job of expediting oncology indications despite being cash hungry.
Neither drug has ever shown any real side effects. Not sure what you're trying to say. Your wording makes me wonder if you're familiar with Galectin's drug. Are you? Just wondering - not trying to be antagonistic.
Market Data 
Markets 
AI
